AstraZeneca Initiates CALAVI Study Evaluating Calquence (acalabrutinib) Against COVID-19
Shots:
- The CALAVI study is a two-part trial assessing the efficacy and safety of Calquence + BSC vs BSC as monothx. in patients hospitalized with respiratory complications of COVID-19
- Part 1 randomized patients in a ratio (2:1) and evaluates Calquence + BSC in patients who are hospitalized- but not on assisted ventilation & not in the ICU while part two evaluates therapy in a cohort of patients in the ICU with more severe respiratory complications
- The goal of the study to reduce mortality and the need for assisted ventilation in patients with life-threatening COVID-19 symptoms. Calquence is a BTK inhibitor act by binding covalently to BTK further inhibiting its activity in the beta-cell
Click here to read full press release/ article
Ref: AstraZeneca | Image: Student Show
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com